Ferring Pharmaceuticals today announced the recipients of the 2018-19 Ferring Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.
Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer…
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance…
Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian…
Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial…
Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin…
Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure…
Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring…
On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia…
Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan®…
This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.
OKCette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.
OKIk bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals
OKEz az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.
OKTa strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.
OKЭта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.
OK